Analysis of choroidal thickness in eyes treated with focal laser photocoagulation using SD-OCT

Adhi, Mehreen; Alwassia, Ahmad A.; Duker, Jay S.

doi:10.1016/j.jcjo.2013.05.010

Cited by 12 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, focal laser treatment has been shown to improve vision and anatomy without choroidal thinning. 22 Finally, various studies indicate that anti-VEGF injections may result in choroidal thinning in AMD also, 20, 21 further implying that the effect is not specific to the disease process in DME. VEGFa has a known trophic effect on maintaining the choroidal vasculature.…”

Section: Discussionmentioning

confidence: 99%

“…Other exclusion criteria include high myopia >6 diopters, history of glaucoma, presence of vitreomacular traction, and history of vitreoretinal surgery. Since choroidal thickness has been shown to be unaffected by focal laser therapy, 22 eyes with prior focal laser treatment were not excluded. Only one eye from each subject was included for analysis.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Anti–Vascular Endothelial Growth Factor Therapy on Choroidal Thickness in Diabetic Macular Edema

Yiu

Manjunath

Chiu

et al. 2014

American Journal of Ophthalmology

100

View full text Add to dashboard Cite

Purpose To determine the effect of anti-vascular endothelial growth factor (VEGF) therapy on choroidal thickness in eyes with diabetic macular edema (DME) Design A retrospective, cohort analysis of 59 eyes from 59 patients with DME without prior anti-VEGF therapy Methods Choroidal thickness was measured using semi-automated segmentation of enhanced-depth imaging optical coherence tomography (EDI-OCT) images at 0.5mm intervals from 2.5mm nasal to 2.5mm temporal to the fovea. Changes in choroidal thickness with and without anti-VEGF treatment over 6 months were compared. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were analyzed to evaluate the association of choroidal thickness with functional and anatomical outcomes. Results Of the 59 eyes with DME, 26 eyes were observed without treatment, while 33 underwent intravitreal anti-VEGF therapy (mean number of injections = 2.73) over 6 months. In untreated eyes, there was no significant change in BCVA (p=0.098), CFT (p=0.472), or choroidal thickness at all measurements along the macula (p=0.057 at the fovea). In eyes treated with anti-VEGF injections, choroidal thickness significantly decreased at the fovea (246.6μm to 224.8μm; p<0.001) and at 0.5 mm nasal (240.9μm to 221.9μm; p = 0.002) and 0.5 mm temporal (249.3μm to 224.8μm; p=0.011) to the fovea. The decrease in subfoveal choroidal thickness after anti-VEGF treatment was not associated with the cumulative number of anti-VEGF injections (R2=0.031, p=0.327), or to changes in BCVA (R2=0.017; p=0.470) or CFT (R2=0.040; p=0.263). Conclusions Central choroidal thickness decreases after anti-VEGF therapy for DME after 6 months, but may not be associated with functional or anatomical outcomes in eyes with DME.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Effect of Anti–Vascular Endothelial Growth Factor Therapy on Choroidal Thickness in Diabetic Macular Edema

Yiu

Manjunath

Chiu

et al. 2014

American Journal of Ophthalmology

100

View full text Add to dashboard Cite

show abstract

“…In addition, the thickness of the central choroid seems to increase with progressive nasal and temporal thinning, a pattern that is characteristic of all diabetic patients regardless of DR grade [3,21,22]. Another OCT technology, sweptsource (SS)-OCT, uses a different light source and detection method, and offers the advantages of higher imaging speed and accuracy, which are important in analyzing the choroid [23][24][25][26][27]. Lastly, the recent development of OCT angiography enables non-invasive visualization of vascular structures based on the motion of erythrocytes within the retinal and choroidal vasculature.…”

Section: Imaging the Choroidmentioning

confidence: 99%

Diabetic choroidopathy: a review of the current literature

Melância

Vicente

Cunha

et al. 2016

Graefes Arch Clin Exp Ophthalmol

120

106

View full text Add to dashboard Cite

Diabetic retinopathy is an increasingly prevalent disease, and a leading contributor to the burden of all-cause blindness worldwide. In addition to retinal changes, choroidal abnormalities are common in patients with diabetes. The first studies concerning this vascular structure were based on histologic, indocyanine angiography and laser Doppler flowmetry techniques, but the development of new optical coherence tomography (OCT) technologies and imaging software for enhanced depth imaging (EDI)-OCT in recent years has made it possible to provide more detailed images of the choroidal anatomy and topography.In diabetic patients, several choroidal changes have been described in the literature throughout the years; the recent focus is choroidal thickness, which is significantly different from that in healthy patients. However, understanding choroidal manifestations of diabetic eye disease remains a real challenge, and this gap is hindering efforts towards better defining choroidal evaluation as a predictive factor for disease evolution and treatment response.This review aims to summarize the recent literature concerning changes in choroidal structure in diabetic patients, the relationship to diabetic retinal disease progression, and finally, the current and potential application of the measurement of variations in choroidal thickness for patient management.

show abstract

“…However, there are serious limitations in that study: small cohort, no EDI procedure, scans only within 500 μ m from the fovea where laser burns would unlikely be present, short follow‐up and set of data from focal scans only, without determination of an area of CT (Adhi et al. ).…”

Section: Choroid and Diabetesmentioning

confidence: 99%

Viewing the choroid: where we stand, challenges and contradictions in diabetic retinopathy and diabetic macular oedema

Campos

Martins

et al. 2016

Acta Ophthalmologica

View full text Add to dashboard Cite

Diabetic macular oedema (DMO) is the leading cause of vision loss in the working-age population. Blood-retinal barrier (BRB) dysfunction in diabetic retinopathy (DR), mainly at the level of the retinal vessels, has long been related with leakage and fluid accumulation, leading to macular oedema. However, the nourishment of the macula is provided by the choroid and a diabetic choroidopathy has been described. Therefore, there has been a growing interest in studying the role of the choroid in the pathophysiology of DR and DMO, mainly by optical coherence tomography (OCT). Nevertheless, there are conflicting results in the different studies. We summarize the results from the available studies, describe the limitations and confounding factors and discuss future procedures to avoid bias.

show abstract

Analysis of choroidal thickness in eyes treated with focal laser photocoagulation using SD-OCT

Cited by 12 publications

References 16 publications

Effect of Anti–Vascular Endothelial Growth Factor Therapy on Choroidal Thickness in Diabetic Macular Edema

Effect of Anti–Vascular Endothelial Growth Factor Therapy on Choroidal Thickness in Diabetic Macular Edema

Diabetic choroidopathy: a review of the current literature

Viewing the choroid: where we stand, challenges and contradictions in diabetic retinopathy and diabetic macular oedema

Contact Info

Product

Resources

About